Honigman partners present on America Invests Act at international conference


from local sources

Honigman Miller Schwartz and Cohn Partners Kelly T. Murphy and Fernando Alberdi, Ph.D., in the firm’s Intellectual Property and Technology Department, recently participated in a panel entitled America Invents Act Comes to Campus: the Impact on Commercialization and Technology Transfer Offices at the 2012 BIO (Biological Industry Organization) International Convention in Boston, Massachusetts. The Leahy-Smith America Invents Act (AIA) of 2011 significantly changes U.S. patent law and will greatly impact the life science industry.

The panel discussed the new law’s effect on universities and non-profit research institutions and provided pragmatic approaches to meet the new requirements, while at the same time improving timely technological disclosures. Audience members praised the presentation for “its laser focus on key practice issues” and for the “insight provided into the effects on the National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health (NIH).”

Murphy is located in Honigman’s Kalamazoo office. He counsels clients on government contracts, grants and procurement regulations, and assists in patent procurement, regulatory compliance and negotiation of licensing agreements for domestic/international pharmaceutical and bio
technology companies, nonprofits and academic institutions. He earned a J.D. from Columbus School of Law, Catholic University of America, as well as an M.S. with an emphasis in molecular biology and a B.S. in biological sciences from Western Michigan University.

Alberdi, who is in the firm’s Ann Arbor office, counsels clients on patent preparation and prosecution, particularly in the areas of life science, chemical, and biopharmaceutical, bioengineering and biotechnological arts. Alberdi also assists clients in procuring and enforcing domestic and international patents; conducting intellectual property due diligence; and preparing legal opinions on patent validity and/or patent non-infringe-
ment. He earned a J.D., magna cum laude, at Michigan State Univ. College of Law, a Ph.D. in Biochemistry and Immunology and a B.App.Sc. Biotechnology at Royal Melbourne Institute of Technology University.

BIO is the world’s largest biotechnology organization, a 503c non-profit headquartered in Washington, D.C., providing advocacy, business development, and communications services for more than 1,100 members worldwide.